Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.
Typically, EGFR inhibitors are used in lung and colon cancer to treat patients with KRAS mutations. However, this therapy has mixed clinical outcomes for the patients, varying by their mutation subtype. Chu emphasizes that nurses and doctors must use the EGFR inhibitors wisely, and consider the patient’s subtype when deciding on a treatment plan.